Uzbekistan combines Central Asia's largest population, a rapidly modernizing healthcare system, growing pharmaceutical investment, and patient access across cardiovascular, oncology, infectious disease, and metabolic research areas.
Uzbekistan is Central Asia's most populous nation; a doubly-landlocked republic of approximately 36 million people at the heart of the ancient Silk Road, bordered by Kazakhstan to the north, Kyrgyzstan and Tajikistan to the east and southeast, Afghanistan to the south, and Turkmenistan to the west. Tashkent, the capital and by far the region's largest city (~3.5 million), is the unambiguous centre of the country's medical, academic, and clinical research activity and the most accessible international hub in Central Asia with direct flights to Europe, Russia, China, Turkey, and the Gulf. Samarkand (~600,000), Namangan (~700,000), Andijan (~450,000), Bukhara, and Fergana host regional medical institutes and hospital infrastructure extending clinical research capacity well beyond the capital. Since 2016, President Shavkat Mirziyoyev has implemented one of the most substantial economic reform agendas in the post-Soviet space; opening currency markets, liberalizing foreign investment regulation, privatizing state enterprises, and specifically targeting the healthcare and pharmaceutical sectors for international investment attraction.
Clinical trials in Uzbekistan are regulated by the Ministry of Health of the Republic of Uzbekistan, which oversees clinical trial authorization, GCP compliance, and national pharmaceutical policy. The Agency for the Development of the Pharmaceutical Industry of Uzbekistan has been established under the reform agenda to attract international pharmaceutical investment and streamline regulatory processes for foreign sponsors. Ethics review is conducted through the Republican Bioethics Committee under the Ministry of Health. Uzbekistan is not a member of the EAEU, EU, or ICH, but its regulatory framework has been actively modernizing toward alignment with WHO and ICH-GCP standards since 2016, with streamlined CTA approval processes specifically designed to reduce barriers to international sponsor entry. Uzbekistan's pharmaceutical market; historically dominated by imports; has grown significantly with rising health expenditure and is estimated at approximately $1.5–2 billion annually, attracting growing CRO and sponsor investment.
Uzbekistan's population is approximately 84% ethnic Uzbek; a Turkic people whose distinct Central Asian genetic lineage reflects the deep nomadic, sedentary agricultural, and Silk Road trading heritage of the region; with Tajik (~3%), Russian (~3.5%), Kazakh (~2.5%), Karakalpak (~1%), and Kyrgyz and other minority communities. With a median age of approximately 28 years, Uzbekistan has one of the youngest population structures of any country in the broader Eurasian research landscape; a demographic profile that is structurally distinctive from the aging populations of Eastern Europe and creates specific trial design opportunities across paediatric indications, reproductive health, infectious disease, and early-onset disease programs that require younger patient cohorts. Literacy stands at approximately 99.9%; a Soviet-era educational legacy that has proven highly durable. Russian remains widely used in medical and scientific settings among the older investigator generation, while Uzbek is dominant in everyday clinical practice; English proficiency is growing steadily among a new generation of investigators trained at internationally partnered institutions and exposed to global clinical trial networks.
Uzbekistan's disease burden is dominated by cardiovascular disease, which accounts for approximately 55–60% of national mortality and generates patient pools for hypertension, coronary artery disease, heart failure, and stroke that are both vast in scale and substantially treatment-naïve relative to modern pharmacotherapy. Cancer is the second-leading cause of death, with a distinctive oncological profile: Uzbekistan carries among the highest cervical cancer rates in Central Asia, driven by high HPV prevalence and historically limited screening infrastructure, alongside significant colorectal, gastric, lung, and liver cancer burdens. Infectious disease adds a third pillar; hepatitis B and C have historically elevated prevalence linked to unsafe medical injection practices in earlier decades, TB (including MDR-TB) remains a public health challenge, and brucellosis maintains a presence in rural agricultural communities. Metabolic disease, particularly Type 2 diabetes, is expanding rapidly as Uzbekistan urbanises and dietary patterns shift. Respiratory disease; including dust-related pathology from the partially desiccated Aral Sea basin affecting the northwestern Karakalpakstan region; adds a further distinctive environmental health dimension unique to this geography.
The most under-trialed major population in Eurasia: Uzbekistan's clinical research penetration rate is striking in its contrast with its demographic scale. With approximately 36 million people; a population broadly comparable to Poland, Ukraine, or Morocco; Uzbekistan has fewer than 250 registered studies on ClinicalTrials.gov. Kazakhstan, with roughly half Uzbekistan's population, has more than twice as many. The gap between Uzbekistan's population scale and its current trial volume is wider than that of any comparable Eurasian market; and it is precisely this gap that defines the early-mover opportunity. Sponsors who develop site relationships and CRO infrastructure in Tashkent now will be building a structural advantage in Central Asia's largest market before the commercialisation wave arrives.
Uzbekistan's proposition is first-mover scale: Central Asia's largest domestic population in the early stages of clinical research commercialisation, a government that has made pharmaceutical market opening an explicit policy priority, per-patient economics that rank among the most competitive in the entire Eurasian research landscape, and a network of Republican Specialized Scientific and Practical Medical Centres in Tashkent that provides a concentrated, specialist research infrastructure for the country's major therapeutic areas.
Ministry of Health authorization; Republican Bioethics Committee ethics review; progressive regulatory modernization toward WHO and ICH-GCP standards since 2016; Agency for Development of Pharmaceutical Industry specifically created to attract and accelerate international sponsor entry; government-mandated streamlining of CTA approval timelines as part of the broader pharmaceutical investment attraction agenda.
Per-patient and site operational costs among the lowest in Eurasia; significantly below Kazakhstan, Russia, and all Eastern European comparators; investigator fees and site overhead reflecting a lower-middle-income economy undergoing rapid growth; some of the strongest cost-efficiency ratios in the broader Eurasian clinical research landscape for sponsors building high-volume enrollment programs.
36 million people; Central Asia's largest patient market; vast cardiovascular and oncology treatment-naïve pools from a population with limited prior advanced pharmacotherapy exposure; world's highest cervical cancer rates in the region for oncology HPV programs; young median age (~28 years) enabling paediatric and early-onset disease program designs unavailable in aging European markets; high trial motivation.
Network of Republican Specialized Scientific and Practical Medical Centres (RSNPMCs) covering oncology, cardiology, haematology, endocrinology, pulmonology, and neurology in Tashkent; Tashkent Medical Academy and 10+ medical institutes nationwide sustaining the investigator pipeline; international CRO infrastructure beginning to establish in Tashkent; direct air connectivity from Tashkent to all major Eurasian, European, and Gulf monitoring hubs.
Cardiovascular disease anchors Uzbekistan's trial portfolio with a mortality burden that places it among the highest in the Eurasian region; creating large-scale, treatment-naïve patient pools across hypertension, coronary artery disease, heart failure, and stroke that are accessible through the Republican Specialized SPMC of Cardiology and the major Tashkent clinical hospital networks. Oncology is characterized by two distinctive features: among the highest cervical cancer incidence rates in Central Asia; creating a patient population of particular relevance to HPV-targeted immunology and gynaecologic oncology programs; and a broad rising incidence of gastric, colorectal, and liver cancer driven by H. pylori burden and HCV-related hepatic disease. Infectious disease carries three specific pillars; hepatitis B and C with well-characterized historical transmission epidemiology, MDR-TB with an established national management program, and brucellosis in rural populations. Metabolic disease is the fastest-growing therapeutic area, reflecting rapid urbanisation. Paediatric indications benefit distinctly from Uzbekistan's demographic youth. Environmental health; particularly respiratory and oncological disease in the Karakalpakstan region affected by Aral Sea desiccation; creates a genuinely unique research niche with no comparator elsewhere in Central Asia.
Tashkent overwhelmingly dominates Uzbekistan's clinical research landscape. The city's network of Republican Specialized Scientific and Practical Medical Centres (RSNPMCs); national specialist institutions for oncology, cardiology, haematology, endocrinology, pulmonology, and neurology; collectively form the country's most concentrated clinical research infrastructure. The Tashkent Medical Academy clinical campus and the Tashkent Pediatric Medical Institute complement the specialist centres with broad multispecialty and paediatric coverage. Regional institutes in Samarkand, Andijan, and Bukhara provide geographic reach into the densely populated Fergana Valley and the ancient Silk Road corridor, extending enrollment breadth for multi-site national trial designs.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Tashkent Medical Academy Clinical Hospital | Tashkent | The primary clinical teaching and research base of Tashkent Medical Academy (TMA), Uzbekistan's oldest and most prestigious medical institution (founded 1919); Phase II–IV across internal medicine, cardiology, oncology, neurology, and endocrinology; the principal anchor site for the national investigator pipeline and the primary portal for international sponsors building first Uzbekistani site relationships; strong post-2016 international research exchange activity. |
| 02 | Republican Specialized Scientific and Practical Medical Centre of Oncology and Radiology | Tashkent | Uzbekistan's national cancer centre and the primary oncology research institution; Phase II–IV across solid tumours and haematologic malignancies; the country's leading site for cervical cancer, gastric, colorectal, and liver cancer trial programs; TMA affiliate; houses the national oncology registry; the principal clinical research partner for international oncology sponsors entering the Uzbekistani market. |
| 03 | Republican Scientific Center of Emergency Medical Aid | Tashkent | Uzbekistan's national emergency and acute care centre with major cardiovascular and surgical research capability; Phase II–IV in cardiac surgery, cardiovascular disease, trauma surgery, and acute internal medicine; large acute patient throughput from across Uzbekistan as the national emergency referral centre; an important site for sponsors in cardiovascular intervention, acute stroke, and emergency medicine programs. |
| 04 | Republican Specialized Scientific and Practical Medical Centre of Cardiology | Tashkent | Uzbekistan's dedicated national cardiology research and treatment centre; Phase II–IV cardiovascular outcome trials, heart failure, hypertension, arrhythmia, and interventional cardiology studies; modern cardiac imaging and catheterisation laboratory infrastructure; the deepest cardiovascular investigator team in the country with a national patient referral catchment that reflects Uzbekistan's very high cardiovascular mortality burden. |
| 05 | Republican Specialized Scientific and Practical Medical Centre of Haematology | Tashkent | Uzbekistan's national specialist centre for blood diseases and haematological oncology; Phase II–IV in haematologic malignancies including lymphoma, leukaemia, myeloma, and MDS; the primary site for bone marrow transplant and cell therapy–related trial programs; TMA affiliate; large treatment-naïve haematologic patient catchment given limited prior access to advanced biologic haematology therapies through standard care. |
| 06 | Republican Specialized Scientific and Practical Medical Centre of Endocrinology | Tashkent | Uzbekistan's national endocrinology and diabetes centre; Phase II–IV in Type 1 and Type 2 diabetes, thyroid disease, adrenal disorders, and metabolic syndrome; large and rapidly expanding treatment-naïve diabetic patient pool driven by Uzbekistan's accelerating metabolic disease burden as urbanisation and dietary transition accelerate; TMA affiliate with growing international sponsor engagement in cardiometabolic drug development programs. |
| 07 | Republican Specialized Scientific and Practical Medical Centre of Pulmonology | Tashkent | Uzbekistan's national pulmonology and TB specialist centre; Phase II–IV in pulmonary TB, multidrug-resistant TB (MDR-TB), COPD, asthma, and interstitial lung disease; well-characterised TB patient cohort including MDR and XDR strains of direct relevance to anti-infective drug development pipelines; established WHO-affiliated TB research program with experience in international anti-TB clinical trial protocols. |
| 08 | Tashkent Pediatric Medical Institute Hospital | Tashkent | Uzbekistan's dedicated national paediatric medical institution and the primary research base for paediatric clinical trials; Phase II–IV in paediatric oncology, infectious disease, rare genetic diseases, and metabolic disorders; an institution of particular value given Uzbekistan's young population structure; children and adolescents represent a substantially larger share of the national population than in any European comparator market, creating paediatric enrollment opportunities unavailable elsewhere in Eurasia. |
| 09 | Republican Specialized Scientific and Practical Medical Centre of Neurology | Tashkent | Uzbekistan's national neurology research centre; Phase II–IV in stroke, epilepsy, multiple sclerosis, Parkinson's disease, and neurodegenerative disorders; large treatment-naïve neurological patient cohort reflecting the population's limited prior access to modern neurological pharmacotherapy; TMA affiliate with active participation in CIS neurology research networks and growing international sponsor engagement. |
| 10 | Samarkand State Medical Institute Hospital | Samarkand | The primary clinical research base of Samarkand State Medical Institute (SamMI), one of Central Asia's oldest medical faculties; Phase II–III across cardiovascular, oncology, and internal medicine; serves the Samarkand region's large and historically distinct population; important second-city site for multi-centre Uzbekistani trial designs; proximity to Bukhara and the ancient Silk Road corridor extends southern Uzbekistani patient access. |
| 11 | Andijan State Medical Institute Hospital | Andijan | The clinical base of Andijan State Medical Institute, serving the densely populated Fergana Valley; one of the most populous sub-regions in Central Asia; Phase II–III in cardiovascular disease, oncology, and internal medicine; geographic access to the Uzbekistani-Tajik-Kyrgyz border triangle's patient populations; key node for sponsors seeking broad Fergana Valley enrollment coverage in multi-site national designs. |
| 12 | Bukhara Regional Clinical Hospital | Bukhara | The primary hospital complex serving the Bukhara region of central Uzbekistan; Phase II–III in cardiovascular disease, oncology, and internal medicine; access to a large regional patient population with historically distinct agricultural and rural exposure patterns; developing clinical research capacity as Uzbekistan's national research network expands beyond Tashkent and the major medical institute cities. |
The primary clinical teaching and research base of Tashkent Medical Academy (TMA), Uzbekistan's oldest and most prestigious medical institution (founded 1919); Phase II–IV across internal medicine, cardiology, oncology, neurology, and endocrinology; the principal anchor site for the national investigator pipeline and the primary portal for international sponsors building first Uzbekistani site relationships; strong post-2016 international research exchange activity.
Uzbekistan's national cancer centre and the primary oncology research institution; Phase II–IV across solid tumours and haematologic malignancies; the country's leading site for cervical cancer, gastric, colorectal, and liver cancer trial programs; TMA affiliate; houses the national oncology registry; the principal clinical research partner for international oncology sponsors entering the Uzbekistani market.
Uzbekistan's national emergency and acute care centre with major cardiovascular and surgical research capability; Phase II–IV in cardiac surgery, cardiovascular disease, trauma surgery, and acute internal medicine; large acute patient throughput from across Uzbekistan as the national emergency referral centre; an important site for sponsors in cardiovascular intervention, acute stroke, and emergency medicine programs.
Uzbekistan's dedicated national cardiology research and treatment centre; Phase II–IV cardiovascular outcome trials, heart failure, hypertension, arrhythmia, and interventional cardiology studies; modern cardiac imaging and catheterisation laboratory infrastructure; the deepest cardiovascular investigator team in the country with a national patient referral catchment that reflects Uzbekistan's very high cardiovascular mortality burden.
Uzbekistan's national specialist centre for blood diseases and haematological oncology; Phase II–IV in haematologic malignancies including lymphoma, leukaemia, myeloma, and MDS; the primary site for bone marrow transplant and cell therapy–related trial programs; TMA affiliate; large treatment-naïve haematologic patient catchment given limited prior access to advanced biologic haematology therapies through standard care.
Uzbekistan's national endocrinology and diabetes centre; Phase II–IV in Type 1 and Type 2 diabetes, thyroid disease, adrenal disorders, and metabolic syndrome; large and rapidly expanding treatment-naïve diabetic patient pool driven by Uzbekistan's accelerating metabolic disease burden as urbanisation and dietary transition accelerate; TMA affiliate with growing international sponsor engagement in cardiometabolic drug development programs.
Uzbekistan's national pulmonology and TB specialist centre; Phase II–IV in pulmonary TB, multidrug-resistant TB (MDR-TB), COPD, asthma, and interstitial lung disease; well-characterised TB patient cohort including MDR and XDR strains of direct relevance to anti-infective drug development pipelines; established WHO-affiliated TB research program with experience in international anti-TB clinical trial protocols.
Uzbekistan's dedicated national paediatric medical institution and the primary research base for paediatric clinical trials; Phase II–IV in paediatric oncology, infectious disease, rare genetic diseases, and metabolic disorders; an institution of particular value given Uzbekistan's young population structure; children and adolescents represent a substantially larger share of the national population than in any European comparator market, creating paediatric enrollment opportunities unavailable elsewhere in Eurasia.
Uzbekistan's national neurology research centre; Phase II–IV in stroke, epilepsy, multiple sclerosis, Parkinson's disease, and neurodegenerative disorders; large treatment-naïve neurological patient cohort reflecting the population's limited prior access to modern neurological pharmacotherapy; TMA affiliate with active participation in CIS neurology research networks and growing international sponsor engagement.
The primary clinical research base of Samarkand State Medical Institute (SamMI), one of Central Asia's oldest medical faculties; Phase II–III across cardiovascular, oncology, and internal medicine; serves the Samarkand region's large and historically distinct population; important second-city site for multi-centre Uzbekistani trial designs; proximity to Bukhara and the ancient Silk Road corridor extends southern Uzbekistani patient access.
The clinical base of Andijan State Medical Institute, serving the densely populated Fergana Valley; one of the most populous sub-regions in Central Asia; Phase II–III in cardiovascular disease, oncology, and internal medicine; geographic access to the Uzbekistani-Tajik-Kyrgyz border triangle's patient populations; key node for sponsors seeking broad Fergana Valley enrollment coverage in multi-site national designs.
The primary hospital complex serving the Bukhara region of central Uzbekistan; Phase II–III in cardiovascular disease, oncology, and internal medicine; access to a large regional patient population with historically distinct agricultural and rural exposure patterns; developing clinical research capacity as Uzbekistan's national research network expands beyond Tashkent and the major medical institute cities.
These are the primary regulatory, academic, and industry bodies shaping Uzbekistan's clinical research ecosystem.
Uzbekistan's primary regulatory authority for clinical trial authorization, GCP compliance, and national pharmaceutical policy; oversees the Republican Bioethics Committee and all clinical trial authorization processes; operating under a progressively modernizing regulatory framework aligned with WHO and ICH-GCP standards since the 2016 reform agenda, with specific mandates to reduce barriers to international sponsor entry.
Established under Mirziyoyev's reform program specifically to attract and facilitate international pharmaceutical investment and clinical research; coordinates regulatory streamlining for foreign sponsors, manages pharmaceutical market development strategy, and serves as the primary institutional interlocutor for international companies entering the Uzbekistani pharmaceutical and clinical research market for the first time.
The national ethics review body responsible for clinical trial protocol evaluation in Uzbekistan, operating under the Ministry of Health; provides a centralized ethics review process for all trials conducted at Uzbekistani research sites; working with the Ministry of Health's reform agenda to align ethics review timelines with international sponsor expectations for multi-country CIS trial submissions.
Uzbekistan's oldest and most prestigious medical university, founded in 1919 and the backbone of the national investigator pipeline across all major therapeutic areas; affiliated with the Republic Specialized SPMC network and the primary TMA Clinical Hospital; drives GCP curriculum modernization, international academic exchange programs, and clinical research partnerships with Russian, Turkish, and increasingly Western European and US institutions.
Central Asia's only dedicated paediatric medical university, uniquely focused on training paediatric physician investigators and conducting paediatric clinical research; the academic anchor for the national paediatric trial portfolio; of particular strategic importance given Uzbekistan's young population structure and the disproportionate scale of the paediatric patient population relative to any European comparator market.
One of Central Asia's oldest medical faculties, founded in 1930 in the ancient Silk Road capital; drives the investigator pipeline for southern Uzbekistani research sites; growing international research exchange programs with Russian, Turkish, and European medical institutions; important regional academic anchor for multi-centre Uzbekistani trial designs covering the central and southern population corridor.
The primary medical university of the Fergana Valley; the most densely populated region of Central Asia; driving the investigator pipeline for eastern Uzbekistani research sites; active research programs in cardiovascular disease and infectious disease reflecting the regional patient burden; a key academic partner for sponsors seeking to maximize enrollment reach across Uzbekistan's most populated sub-region.
CIS-specialist CRO with established Uzbekistani site relationships and a track record across the broader Central Asian and post-Soviet research landscape; Phase II–IV across cardiovascular, oncology, and infectious disease indications; full regulatory submission, contracting, and patient recruitment management under the Ministry of Health framework; well-positioned to support multi-country CIS designs combining Uzbekistani sites with Kazakhstan, Kyrgyzstan, or other regional programs.
Global CRO with CIS regional coverage extending to Uzbekistani sites; Phase II–IV trial management across cardiovascular, oncology, and metabolic indications; Ministry of Health regulatory submission expertise and growing Uzbekistan-specific site network infrastructure; data management and site monitoring capabilities across Tashkent's Republican SPMC network as international sponsor engagement in Uzbekistan accelerates.
International CRO with CIS regional operations covering Central Asia including Uzbekistan; Phase II–IV oncology, cardiovascular, and infectious disease trial management; established investigator relationships across the Tashkent specialist medical centre network; growing capability in multi-country Central Asian trial designs combining Uzbekistani and Kazakhstani sites within a single CIS-regional monitoring and submission framework.
Global CRO with CIS regional operations covering Uzbekistan; Phase II–III trial management and regulatory strategy under the Ministry of Health framework; oncology and cardiovascular therapeutic area depth across the Tashkent hospital network; supports sponsors entering Uzbekistan for the first time or adding Uzbekistani sites to existing CIS multi-country trial portfolios as the market opens under the Mirziyoyev reform agenda.
Uzbekistan offers a large and still developing Central Asian clinical research market, with meaningful patient access, growing medical infrastructure, and increasing policy support for pharmaceutical investment. For sponsors and CROs evaluating regional expansion, the market is most relevant where cardiovascular, oncology, infectious disease, metabolic, and pediatric recruitment needs align with the country's hospital and investigator capacity.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.